Inflammatory Endotypes of Chronic Rhinosinusitis and Impacts on Comorbid Asthma Authors: Francesca Pirola, Claire Hopkins Published: 2026 ABSTRACT AbstractChronic rhinosinusitis (CRS) and asthma frequently coexist and are increasingly understood as manifestations of a shared “united airway” inflammatory process. However, clinical heterogeneity remains substantial, and conventional phenotyping alone does not reliably predict disease trajectory or treatment response across the upper and lower airways. Endotype-based classification, particularly differentiation of type 2 and non-type 2 inflammation, offers a framework that can refine prognostication and support more individualized management. This review synthesizes current evidence linking CRS inflammatory endotypes with asthma severity, exacerbation risk, and postoperative or medical outcomes. We summarize practical biomarkers used in routine care and research settings and discuss how these markers inform therapeutic decisions in CRS with comorbid asthma. In type 2 disease, endotype and biomarker profiles can support a more individualized treatment approach, while also informing escalation pathways in patients with persistent symptoms or recurrence, including consideration of biologic therapy in carefully selected cases. We also highlight limitations of current approaches, including overlap between inflammatory patterns, variability between tissue and systemic biomarkers, and the still-evolving definition of non–type 2 CRS, all of which can limit precision medicine in routine clinical decision-making. Future priorities include standardization of endotype definitions, validation of pragmatic biomarker panels, and integrated multidisciplinary pathways that align upper- and lower-airway outcomes. A biology-informed stratification approach may ultimately enable better patient selection for surgery, corticosteroid strategies, and biologics, improving long-term control of both CRS and asthma. Introduction Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory condition of the upper airways that carries a major health and economic burden, amplified by its frequent comorbid association with lower airway disease. It has been historically categorized into two groups depending on its phenotype, CRS with and without nasal polyps (CRSwNP and CRSsNP, respectively);1 however, it is now recognized as a far more heterogeneous condition that extends beyond this simple phenotypic distinction.2–4 Population data suggests that CRS affects approximately 11–12% of the adult population in Europe and United States, and within these populations CRSwNP ranges between ~2% to 4.4%. Also, across Asia, CRS is among the most frequently diagnosed upper-airway diseases, reaching a prevalence of 8.4% in South Korea (with nasal polyps in 2.5% of cases), and about 1.1% in China.5–7 In this paper we review the epidemiology of CRS and its key comorbidities, particularly asthma and AERD, outline their shared immunologic architecture with emphasis on type 2 biology, and examine how endotype-specific patterns shape clinical severity, quality of life, and treatment response. These relationships have fundamental implications for disease management, particularly for optimizing treatment outcomes within the complex mechanisms of united airways disease. From Phenotypes to Endotypes in CRS Contemporary frameworks moved beyond phenotype to define disease endotypes based on dominant immune pathways that better account for clinical presentation, comorbidity profiles, and therapeutic response. There is a strong convergence towards the recognition of two major categories of inflammatory pathways, type 2 and non-type 2 (including both type 1 and type 3).8 In both instances, epithelial barrier dysfunction and epithelial–immune crosstalk initiate endotype-specific cascades, that create different mediator and cellular circuits that connect sinonasal and bronchial inflammation within the “united airway” paradigm.1,5 Specifically, type 2 inflammation refers to an immune program coordinated by adaptive T-helper 2 (Th2) cells and type 2 innate lymphoid cells (ILC2), with IL-4, IL-5 and IL-13 as its principal effector cytokines.5 Upstream epithelial alarmins, including TSLP, IL-33 and IL-25, can initiate and amplify these pathways. IL-4 and IL-13 promote IgE class-switching, epithelial barrier dysfunction, goblet-cell metaplasia and mucus hypersecretion, whereas IL-5 supports eosinophil maturation, recruitment and survival.1,5 In CRS, type 2 inflammation is therefore commonly associated with tissue and/or blood eosinophilia, increased local or systemic IgE, mast-cell activation, and comorbid asthma or AERD. These features are useful clinical surrogates rather than individually definitive markers, as tissue and circulating biomarkers may be discordant and mixed inflammatory patterns are common.1 Non-type 2 disease shows different inflammatory features, is less frequently tied to asthma, and often has better long-term outcomes (Figure 1). Within this dichotomic distinction, endotypes do not map perfectly onto phenotypes and polyp status, in fact there are subsets of CRSsNP patients that display type 2 signals and asthma comorbidity.1,4,8 These observations position endotyping, rather than phenotyping, as the key determinant of presentation, prognosis, and impact on lower airways.2,8 Figure 1Inflammatory endotypes of the united airway. Schematic overview of type 2 and non-type 2 inflammatory pathways across the upper and lower airways, together with their principal clinical associations and therapeutic implications.In type 2 disease, upper airway involvement is typically characterized by CRSwNP, often associated with eosinophilia and prominent olfactory dysfunction. Shared pathogenic mechanisms include epithelial barrier dysfunction and type 2 cytokine signaling, particularly through IL-4, IL-5, and IL-13. In the lower airway, this inflammatory pattern is commonly associated with eosinophilic asthma and airway hyperresponsiveness. Clinically, type 2 inflammation is characterized by a strong association between upper and lower airway disease and generally greater responsiveness to corticosteroids and type 2-targeted therapies. In non-type 2 disease, upper airway manifestations more commonly include CRSsNP and mixed or neutrophil-predominant inflammatory patterns. Shared mechanisms involve type 1 and type 3 inflammatory pathways, including IFN, TNF, and IL-17 signaling. Lower airway involvement may be characterized by neutrophilic inflammation and variable airway remodeling. Clinically, the association with asthma is generally weaker, and responses to type 2-targeted monoclonal antibodies are less pronounced. The diagram highlights the concept of the “united airway axis,” emphasizing the interconnected inflammatory mechanisms linking the upper and lower airways.Diagram of airway inflammatory endotypes: type 2 and non-type 2 pathways. Inflammatory endotypes of the united airway. Schematic overview of type 2 and non-type 2 inflammatory pathways across the upper and lower airways, together with their principal clinical associations and therapeutic implications. Endotypes also structure therapeutic choices. In this context, surgery and topical anti-inflammatory therapy remain foundational, but since the introduction of monoclonal antibodies (mAbs) more emphasis has been put on identifying objective and reliable markers of type 2 inflammation to guide precision medicine. In fact, the development of type 2-directed mAbs has offered improvement in upper and lower airway outcomes and quality of life (QoL), especially in patients with more severe conditions and tendency to frequent relapse or disease exacerbations.9–11 In contrast, targeted options for non-type 2 CRS are still relatively limited. In this category, patients still benefit more often from optimized topical therapy and comprehensive surgery, macrolide-based anti-inflammatory regimens in selected cases, culture-directed antibiotics for acute bacterial exacerbations, and revision surgery for recalcitrant disease.12–14 Unfortunately, the majority of studies looking at both the natural history of CRS and the impact of different treatment options, including those that have examined the relationship between CRS and its comorbidities – particularly asthma – and the effects of treating one condition on outcomes in the other, have stratified patients only by polyp status and do not incorporate data on the underlying endotypes. This limitation will become apparent in the discussion that follows. Epidemiology of CRS and Its Lower Airways Comorbidities CRS phenotypes display substantial endotypic heterogeneity, with geographical differences in epidemiology and immunology. Western populations typically display a predominance of type 2 inflammation across both CRS with and without NP.13 Although non-type 2 signatures have historically predominated in Asian patients, recent studies describe a sharp rise in type 2 disease over the past two decades, making this an “eosinophilic shift” that is reshaping regional inflammatory profiles.5–7 Prospective surgical cohorts indicate that 85–93% of CRSwNP meets EPOS/EUFOREA criteria for type 2 disease, and within this type 2 stratum asthma and aspirin-exacerbated respiratory disease (AERD) are the most frequent comorbidities.5,12,15 Figures slightly vary in different cohorts, but proportions remain similar across studies. For example, in a Brazilian cohort analyzed by Zucoloto et al,15 the type-2 CRS subgroup accounted for 78% of overall CRS and was associated with markedly higher prevalences of nasal polyps (93%), asthma (40.3%), and AERD (17.5%) compared to the non-type 2 CRS subgroup (12.5%, 12.5%, and 0%, respectively). The link between CRS and asthma is bidirectional. Asthma has a prevalence of 5–10% in the general population. In population-based data centered on phenotypes of CRS, it has been reported that 20–60% of CRSwNP patients suffer from asthma, compared with less than 10% among CRSsNP patients.16,17 Conversely, about 40–50% of asthmatics exhibit radiological or clinical features of CRS.18 In the UK CRES study by Philpott et al, data from 1470 participants was analyzed, showing asthma prevalence rising from about 10% in healthy controls to 21% in CRSsNP, 47% in CRSwNP and more than 70% in allergic fungal rhinosinusitis (AFRS).17 These findings mirror the European “one-airway” concept first defined in the GA2LEN survey, in which CRS was associated with about 3.5-fold higher odds of asthma and even higher if allergic rhinitis coexisted (adjusted OR 11.85).16,19,20 Using data from more than 330,000 individuals in the Korean National Health Insurance Service sample cohort, Ryu et al18 showed that the presence of asthma increased the subsequent risk of CRS (adjusted HR=1.74), as well as CRS increased the risk of asthma onset (HR=1.85).18 The available data is still mostly based on CRS phenotypes rather than on endotypes-driven clustering. Other lower-airway disorders may also coexist with CRS. AERD affects 5–15% of asthmatics and 15–25% of CRSwNP patients in Europe, and is associated with a heavier disease burden, difficult-to-treat disease, and increased risks of exacerbation and post-surgical recurrence.16,17,18 The prevalence estimates of AERD are limited by the lack of blinded aspirin challenges in patients with CRSwNP and/or asthma, but overall are relatively consistent across different studies and populations.21 Conversely, nearly all patients with AERD present with nasal polyps and asthma, with studies showing rates around 80% to 100%.22,23 Bronchiectasis likewise fits within the “united airways” framework. Among 88 patients with bronchiectasis included in a study by Guilemany et al, the prevalence of CRS and specifically CRSwNP has been reported as high as 77% and 26% respectively.24 Population-level analyses also suggest strong bidirectional associations between CRS and bronchiectasis.25 In a large cohort study by Peters et al, patients with CRS had a higher frequency of concurrent bronchiectasis (24.3%) than those with asthma (19.5%).26 However, these associations do not establish causality, and the mechanisms underlying the coexistence of CRS and bronchiectasis remain uncertain. In some patients, both conditions may arise from a shared mucociliary disorder, such as cystic fibrosis or primary ciliary dyskinesia, accounting for simultaneous upper- and lower-airway involvement.27 Other patients may present with coexisting CRS and bronchiectasis characterized by eosinophilic inflammation even in the absence of asthma, suggesting a potentially distinct subgroup.28 Direct bacterial seeding from the sinuses to the lower airways has also been proposed. However, paired sinonasal and bronchial microbiome analyses by Hernaiz-Leonardo et al did not support this mechanism.29 Bronchiectasis should therefore be regarded as an associated lower-airway phenotype and a potential marker of broader airway dysfunction, rather than as a proven consequence of CRS. Extending the united airways paradigm to chronic obstructive pulmonary disease (COPD), Arndal et al found that 22.5% of their 222-patient COPD cohort fulfilled EPOS criteria for CRS (most of whom previously undiagnosed), with CRSwNP being identified in 4.1% of them.30 Available CRS data suggest a predisposition to lower-airway comorbidities; accordingly, these findings support routine assessment of the upper airway in patients with chronic lower-airway disease, and vice versa. However, endotype-stratified subgroup analyses – particularly in large cohorts – are challenging because of the substantial heterogeneity of both upper and lower airway disease and the availability of specific biomarkers. Consequently, this remains an active area of investigation.13,31 Pathophysiology of CRS and Its Relationship with Asthma CRS is best understood not as a single disease but as a spectrum of endotypes defined by dominant immune pathways. The most clinically useful endotyping distinguishes type-2 inflammatory pattern from non-type 2, which encompasses type-1-dominant (IFN-γ/TNF-α-skewed) and type-3/neutrophilic (Th17/IL-17-rich) inflammation. Overlapping features of type 2 with type 1/type 3 can also be found.32 Both CRS and asthma share core immunologic circuits that link the upper and lower airways, where epithelial barrier dysfunction is a common upstream driver. Damaged epithelial tight junctions increase permeability to pathogens, allergens and other irritants, which are presented to inflammatory cells through toll-like receptors (TLRs) and protease-activated receptors, activating the release of cytokines such as TSLP, IL-33, IL-25.1,33–35 In type 2 disease, these epithelial cytokines orchestrate the immunological reaction by activating specific cell populations: dendritic cells, type 2 innate lymphoid cells (ILC2s), mast cells and Th2 cells. This initial insult and the consequent cascade, creates a feed-forward loop that sustains eosinophilic inflammation, mucosal metaplasia and remodeling in both CRS and asthma. Furthermore, ILC2s and Th2 cells are enriched and spontaneously produce inflammatory cytokines (such as IL-4, IL-5, IL-13) further weakening epithelial barrier function and promoting goblet-cell hyperplasia, IgE class-switching, and eosinophil recruitment. Similar changes are also seen in the bronchial epithelium of asthma patients with type 2 disease.5 Pan-epithelial remodeling is another characteristic of type 2 disease. IL-13-driven metaplasia of goblet cells, basal and tuft-cell expansion, as well as sticky, tenacious mucus are features of the remodeling process in both upper and lower airways.36 In CRSwNP, widespread fibrin deposition reflects the reduced presence of epithelial tissue plasminogen activator (tPA), which is a serine protease that converts plasminogen into plasmin, the enzyme that breaks down fibrin and is part of tissue fibrin clearance. Disproportionate fibrin deposition contributes to impaired mucosal functions and remodeling. In asthma, cytokines such as IL-17A augment airway smooth-muscle contractility, and eosinophilia promotes mucus plugs and collagen changes via eosinophil peroxidase. This enzyme is released when eosinophils degranulate and generates reactive oxidants that help kill microbes but also injure epithelium, thicken and tenacify mucus, and amplify inflammation. All these changes both sustain and are sustained by type 2 inflammation (Figure 2).36 Figure 2Type 2 inflammatory pathways and therapeutic targets in chronic rhinosinusitis with nasal polyps. Schematic representation of some of the epithelial, cellular and cytokine pathways driving type 2 inflammation, and the molecular targets of currently available biologic therapies.The diagram illustrates the main inflammatory pathways and targeted therapies for type 2 chronic rhinosinusitis with nasal polyps. It is divided into three sections: Biologic Therapies, Type 2 Inflammation and Other Pathways. Biologic therapies include Tezepelumab targeting TSLP, Mepolizumab targeting IL-5, Benralizumab targeting IL-5R alpha, Dupilumab targeting IL-4R alpha and Omalizumab targeting IgE. Type 2 inflammation involves epithelial alarmins TSLP, IL-25 and IL-33, which activate ILC2 and Th2 cells, leading to the release of IL-4, IL-5 and IL-13. These cytokines interact with B cells and eosinophils, via IL-4R alpha and IL-5R alpha receptors respectively. They also activate other pathways, such as(1) reduction of tissue plasminogen activator and plasmin, which leads to increased fibrin deposition. (2) B cell dysregulation with autoantibodies production causing persistent inflammation; (3) and hyperactivation of the arachidonic acid pathway producing leukotrienes and prostaglandins.CRSwNP diagram: type 2 inflammation, biologic therapies, cytokine interactions. Type 2 inflammatory pathways and therapeutic targets in chronic rhinosinusitis with nasal polyps. Schematic representation of some of the epithelial, cellular and cytokine pathways driving type 2 inflammation, and the molecular targets of currently available biologic therapies. In contrast, non-type 2 patterns are encountered more often in CRSsNP and, notably, in subsets of Asian patients with CRSwNP, in whom non-eosinophilic, markedly neutrophilic polyps are more prevalent.6 These non-type 2 patterns are less strongly associated with eosinophilia and IgE and are therefore considered less likely to respond to biologics targeting downstream type 2 pathways, such as anti-IL-4/IL-13 or anti-IL-5 therapies.10,32,37 However, this distinction may be less absolute for upstream epithelial alarmin blockade. In the Phase 3 WAYPOINT trial, tezepelumab, an anti-TSLP biologic, improved nasal polyp and nasal congestion scores across all prespecified subgroups stratified by baseline blood eosinophil count, including patients with counts below 150 cells/µL.38 It is unclear if this reflects action against non-type 2 inflammation or the poor sensitivity in detecting type 2 disease of blood eosinophils in CRSwNP.38 In asthma patients with “non-type 2 disease”, neutrophilia, IL-1/IL-8/GM-CSF elevations and reduced steroid responsiveness often coexist as characteristic features. Also in the upper airways, unresponsiveness to systemic steroid is indicative of non-type 2 disease.39,40 Disease Burden in CRS Patients with Comorbid Asthma Various measurement tools have been developed to quantify the impact of CRS and comorbid asthma on health-related quality of life (HR-QoL). The available evidence collected on large cohort studies in different populations suggests an interdependent relationship between CRS and asthma, that synergistically impacts on HR-QoL. In CRS, HR-QoL is most consistently measured with the SNOT-22 questionnaire,41 which also provides subdomain-level analysis; other less disease-specific tools, such as the SF36 and the EQ-5D, are also used and respond to change.11 Recent endotype-aware studies show that type-2 CRSwNP concentrates its burden in smell/taste impairment, rhinorrhea, reduced sleep quality, and psychological distress. In a prospective CRSwNP cohort, type 2 patients had higher total SNOT scores than non-type 2 (SNOT-20 of 39.4 vs 26.7), with the highest reported scores were for loss of smell and rhinorrhea in type 2 patients.12 Similarly, Zucoloto et al15 reported a 15-point drop in SNOT-22 in type 2 CRS versus non-type 2 (53.8 vs 38.8), accompanied by concordant UPSIT-measured olfactory deficits. A tentative analysis to quantify QoL impairment according to the endotype underlying CRS has been published by Wang et al32 Their cohort of CRS patients was divided into 5 clusters based on inflammatory and remodeling factors. Clusters 1 and 2 were defined as having non-type 2 inflammatory patterns given the IL-5 negativity, low eosinophils and neutrophils. Cluster 3 showed low type 2 inflammation, with low expression of IL-5, ECP, GM-CSF and total IgE, therefore with low eosinophils and high neutrophils. Moderate type 2 inflammation (with moderate levels of eosinophils, IL-5, ECP, total IgE, am low neutrophilic count) was observed in cluster 4. Finally, cluster 5 showed high type 2 inflammation, with the highest levels of IL-5, ECP, total IgE, GM-CSF, the highest number of tissue eosinophils per high-power field. Interestingly the authors found that QoL impairment, as well as disease severity and recurrence, increased progressively from clusters 1 to 5, with the greatest impairment seen in patients with high type 2 inflammation (cluster 5) and extensive tissue remodeling. These findings support the clinical relevance of endotyping CRS, as patients with type 2-dominant endotypes (especially those with nasal polyps and comorbid asthma/allergy) experience the most severe symptoms and poorest quality of life.32 Several studies show an amplifying effect of asthma on the link between CRS and poorer QoL. In the analysis performed by Wu et al,42 patients with both CRSwNP and asthma – therefore those more likely to have type 2 disease – showed significantly higher SNOT-22 scores than those without comorbid asthma. The higher scores were found particularly in the rhinologic and sleep-related domains, with the extra burden concentrated in smell and taste loss and in reduced productivity. Phillips et al43,44 added evidence for this interdependent relationship. In patients with both CRS and asthma, the negative impact of CRS on HR-QoL is significantly mediated by the degree of asthma control. Specifically, poorer asthma control, measured by the Asthma Control Test (ACT), accounted for a substantial portion (22%) of the reduction in QoL associated with CRS symptoms (regardless of phenotype or endotype). This finding is supported by additional literature showing that the association between comorbid asthma and decreased quality of life in CRS patients is driven by the clinical status of asthma control, rather than the mere presence of asthma itself.44 Therefore, optimizing asthma control is a key strategy to mitigate quality of life impairment in patients with both CRS and asthma. Conversely, the Swedish GA2LEN survey by Ek et al45 provided detailed data on the impact of CRS on quality of life in patients with asthma. The study included 605 asthmatic subjects, with and without CRS, and used the Mini Asthma Quality of Life Questionnaire (mAQLQ) and the Euro Quality of Life (EQ-5D) health questionnaire to quantify this effect. The results showed that comorbid CRS in asthma is associated with significantly worse asthma-specific and generic quality of life. Among asthmatics, those with CRS had more severe symptom burden, worse lower lung function, and higher morbidity. Precisely, 37% of asthmatics with CRS versus 19% of asthmatic without CRS (p<0.0001) had ≥3–5 asthma symptoms (wheezing, waking with chest tightness, attack of shortness of breath, attack of shortness of breath after strenuous activity, awakening at night with breathlessness). Also, asthmatics with CRS had significantly greater number of asthma attacks in the previous 3 months, nocturnal awakening, and admission in the emergency department in the previous 12 months. Generic QoL was markedly reduced within the asthma and CRS group compared to asthma alone (EQ-5D 0.74 vs 0.85, p<0.001). Asthma-specific QoL, measured by means of the mAQLQ, was significantly lower both in the overall score and in each of the four domains (symptoms, activities, emotions, environment) in subjects having asthma and CRS compared to those with asthma only. Multivariate regression analysis showed that having CRS was an independent negative predictor of asthma-related QoL (p<0.0001), along with lower lung function, current smoking, BMI>30 kg/m2, older age.45 Data is consistent across literature and multiple studies report the significant reduction in QoL in patients that suffer from both CRS and asthma.11,42,43 However, most available QoL analyses are phenotype-based rather than endotype-stratified, and the common dichotomy of “type 2” versus “non-type 2” likely oversimplifies the biological heterogeneity and frequent overlap (“mixed” inflammatory patterns) observed across both CRS and asthma. Sinus Surgery: Effect on Asthma and Its Exacerbations Endoscopic sinus surgery (ESS) has been suggested to improve symptoms of coexisting lower airway comordbitidies.46–48 However, in the setting of endotype-based heterogeneity, the same comorbidity label (such as “asthma”) may reflect distinct underlying biological pathways; as a result, the benefit of sinonasal surgery is unlikely to be uniform across patients. The clinical impact of ESS will depend on the extent to which upper-airway inflammation contributes to the individual’s predominant lower-airway disease mechanism.48,49 Yet, endotype-stratified evidence remains scarce, and most surgical studies treat asthma as a single entity and rarely report outcomes after ESS stratified by CRS or asthma endotypes. A comprehensive metanalysis by Vashishta et al50 in 2013 synthesized 22 studies including 891 patients that evaluated the relationship between sinus surgery and lower airways disease. The pooled percentages from different studies showed that 76% of asthmatic patients reported improvement of their asthma control after surgery, 85% had a decrease in attack frequency, 64% had less episodes needing hospitalization, and 73% reduced oral corticosteroid use. In contrast, consistently with previous single series findings, pooled spirometric indices did not show significant changes. The authors concluded that ESS improves subjective and clinical control of asthma, but not objective lung function, despite their metanalysis lacked randomized control trials. Another metanalysis from Cao et al48 in 2019 contrasted the findings from Vashishta and reported improved pulmonary function (specifically, FEF25–75%, FEV1 and PEF) after ESS in asthmatic patients with either CRSsNP or CRSwNP. The authors, however, emphasized the poor quality of the available evidence as most of the studies included were identified as level 4 evidence. In both meta-analyses, no endotype-based subgroup analyses were performed, since the included primary studies did not report the necessary endotype-stratified data. In a study published in 2020, Tajiri et al evaluated 69 patients with CRS and comorbid asthma undergoing ESS and attempted an endotype-based stratification into eosinophilic and non-eosinophilic group (ECRS and non-ECRS, respectively).51 Endotyping was based on the Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis (JESREC) score52 (>11) and tissue eosinophilia in the ethmoid mucosa or nasal polyps (≥70 eosinophils per high-power field). The impact of ESS on coexisting asthma was assessed six months postoperatively and appeared more pronounced in the non-ECRS group than in the ECRS group. Specifically, ESS was associated with a reduction in asthma exacerbation frequency and in the number of asthma-controlling medications, while pulmonary function did not change significantly, consistent with prior metanalyses. On multivariable logistic regression, older age, no history of previous ESS, and the non-ECRS endotype were independently associated with a greater likelihood of asthma improvement after ESS. Further evidence was provided by Hamada et al53 analyzing a group of 25 eosinophilic CRSwNP patients with uncontrolled asthma who underwent sinus surgery. Among them, 40% reported significant improvement in FEV1, fractional exhaled nitric oxide (FeNO), Asthma Control Questionnaire (ACQ) score, and blood eosinophil count at the post-operative 52 weeks timepoint compared to baseline. In the remaining subjects, the ACQ score showed temporary improvement at 8 weeks after ESS but deteriorated at 52 weeks. Subgroup analysis comparing characteristics at 52 weeks of the improved asthma group versus the unimproved group did not show any significant difference, except for the total serum IgE level which was interestingly higher in the improved group. In AERD, which represents the prototypical type 2 endotype with concomitant severe CRSwNP and asthma,22,54 perioperative management illustrates another way in which sinonasal surgery can be beneficial. In fact, aspirin challenge reactivity decreases after ESS because surgical removal of nasal polyps and inflamed sinus tissue reduces the local inflammatory burden and the production of eicosanoids (such as leukotriene E4 [LTE4] and prostaglandin D2 [PGD2]) that mediate hypersensitivity reactions in AERD.22,23,55 This effect has been demonstrated in prospective studies56 showing that, following ESS, patients with AERD experience less severe reactions during aspirin challenge, or no detectable reaction at all. The reduction in reactivity correlates with lower peripheral blood eosinophilia and decreased urinary LTE4 and plasma PGD2:PGE2 ratio after surgery, indicating a decrease in the underlying inflammatory drivers of aspirin sensitivity.56,57 Therefore, in the AERD endotype, aspirin desensitization can be sequenced in the postsurgical window, potentially improving safety and feasibility in selected patients. Overall, the evidence suggests that while sinus surgery does not reverse long-standing small-airway disease, reducing sinonasal inflammation and obstruction may still yield clinically meaningful benefits by attenuating cough triggers, postnasal-drip–related symptoms, sleep disruption, and overall health status captured by patient-reported outcome measures.16,43,46 Nonetheless, the current literature is insufficiently endotype-stratified to permit meaningful clustering in order to identify which subgroups could derive the greatest benefit from sinus surgery on lower airway disease. Monoclonal Antibodies Treatment Monoclonal antibodies have become the systemic analogue of “endotype control,” because targeting IgE, IL-5/IL-5R, IL-4/IL-13 or TSLP pathways can suppress a shared type-2 mechanism that simultaneously drives severe asthma, CRSwNP, and related comorbidities, thereby offering the possibility of multi-organ benefit within the same patient.58 Therefore, the therapeutic landscape has been transformed by the recognition that disease endotypes influence and predict differential responses to mAbs. In real-world severe asthma populations treated with biologics, comorbidity clustering is common, and improvements after starting a biologic can be evaluated across multiple domains (such as exacerbation rates, asthma control, lung function, and oral corticosteroid use), which are clinically central endpoints for patients who also have CRS and other airway comorbidities.58 Notably, both trial and registry-based analyses suggest that the presence of CRS (with or without polyps) is not merely a coincidental comorbidity but may be associated with greater benefit from mAb in some asthma outcomes, supporting the concept that CRS can serve as a clinical marker of a more biologically responsive type-2-high asthma cluster.58 This concept is increasingly supported by emerging evidence that involve also other biologic drugs. For omalizumab (anti-IgE), patients with severe asthma and comorbid CRSwNP tend to show a greater response, with more pronounced improvements in asthma control, lung function and exacerbation reduction than those without CRSwNP.59 A similar pattern has been observed with benralizumab, where the copresence of asthma and CRSwNP is associated with a higher likelihood of clinically meaningful gains in asthma control, successful withdrawal of maintenance OCS and sustained freedom from exacerbations.60 However, key uncertainties remain around why some patients with coexisting asthma and CRS respond discordantly to type 2-pathway biologics, with clinical practice and small case series describing improvement in asthma control but without equivalent benefit in CRS.61 Although the “united airways” biology is supported by biopsy and provocation studies showing shared Th2/ILC2-driven inflammation across nasal and bronchial mucosa, heterogeneity in histopathologic substrate, remodeling, and drug diffusion across different anatomical areas likely drives different responses to mAbs, underscoring the need for individualized therapeutic strategies.61 Furthermore, heterogeneity within type 2 CRSwNP is illustrated by the variable responses to IL-5-axis biologics, despite their targeting the same inflammatory pathway. Mepolizumab neutralizes soluble IL-5, thereby reducing eosinophil maturation and survival, whereas benralizumab binds IL-5 receptor-α and induces antibody-dependent eosinophil depletion.62 In their respective phase 3 trials, SYNAPSE and OSTRO, both agents improved sinonasal outcomes, although their effects were not equivalent across all disease domains or patient subgroups.63,64 These studies were not designed as head-to-head comparisons and differed in population, endpoints and treatment duration, therefore they cannot establish the superiority of one IL-5-axis strategy over the other. Nevertheless, the differing response patterns suggest that targeting the IL-5–eosinophil axis alone may not uniformly control sinonasal disease, and that additional pathways, cytokines and established tissue remodeling may contribute to persistent inflammation.63,64 Further relevant evidence has been published to support that type 2 CRSwNP is not a single homogeneous cluster, and it does not always respond uniformly to type 2-directed biologics. In 2024 Gayvert et al65 published the results of their study on transcriptomic-based endotyping in CRSwNP patients treated with dupilumab who were enrolled in the SINUS-52 phase 3 trial.66 They performed nasal brushing in the middle meatus of 89 patients within the trial. RNA was extracted from cells and two main transcriptional clusters (C1 and C2) with different biology and clinical response to dupilumab were identified. The gene transcripts were also compared with those of healthy subjects. Both C1 and C2 gene signatures were enriched with upregulation of specific genes associated with type-2 disease, but the gene signature of C2 patients correlated with significantly higher levels of several type 2 biomarkers (such as periostin, IgE, IL-5, eotaxin-3) compared with C1 patients. In contrast, C1 patients showed type 2 gene transcripts but also upregulation of type 3 biomarkers that were not present in the C2 group. Patients’ baseline clinical features did not differ significantly between C1 and C2 groups. Interestingly, a greater proportion of C2 patients demonstrated a clinical response to dupilumab compared to those in C1. Clinically meaningful response in four endpoints (ie, nasal congestion/obstruction, Lund-Mackay score, nasal polyp score, UPSIT score) was defined as according to previously published cutoffs.67 At 24 weeks, 83% of patients met response criteria in at least one endpoint, but only 47% responded across 3–4 endpoints, and these were predominantly in the C2 endotype. Notably, dupilumab efficacy appeared independent of baseline blood eosinophil counts, suggesting that blood eosinophils may not provide additional specificity in identifying treatment responders in CRSwNP populations. This highlighted the substantial heterogeneity of the endotypes within type-2 CRSwNP patients, but no data was provided regarding whether C1 or C2 endotypes correlated with different outcomes in asthma treatment with dupilumab. Ultimately, monoclonal antibodies are endotype-informed tools to modulate a unified airway disease. This reconciles why patients can experience meaningful improvements across comorbid CRS and asthma and supports a treatable-traits strategy in which the dominant biological driver is addressed. There is still not enough evidence to support when and in which patients can benefit mostly from systemic treatment rather than surgery, or a combination of them, to reduce the overall disease burden.50,58,68 Conclusion Chronic rhinosinusitis and asthma represent a “united airway” disease in which shared inflammatory endotypes drive severity, exacerbations, and recurrence. Endotype-informed clinical management, using readily available clinical features and biomarkers, can better predict outcomes and guide selection of surgery, corticosteroid strategies, and biologics. Future work must refine non-type-2 definitions and validate pragmatic biomarker panels for routine practice. Moving toward integrated, multidisciplinary care and standardized endotyping frameworks should improve both upper- and lower-airway control.